JP2024508749A5 - - Google Patents

Info

Publication number
JP2024508749A5
JP2024508749A5 JP2023549562A JP2023549562A JP2024508749A5 JP 2024508749 A5 JP2024508749 A5 JP 2024508749A5 JP 2023549562 A JP2023549562 A JP 2023549562A JP 2023549562 A JP2023549562 A JP 2023549562A JP 2024508749 A5 JP2024508749 A5 JP 2024508749A5
Authority
JP
Japan
Prior art keywords
polypeptide
binding
bispecific molecule
antigen
trbc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023549562A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024508749A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/016423 external-priority patent/WO2022177889A1/en
Publication of JP2024508749A publication Critical patent/JP2024508749A/ja
Publication of JP2024508749A5 publication Critical patent/JP2024508749A5/ja
Pending legal-status Critical Current

Links

JP2023549562A 2021-02-17 2022-02-15 クローンt細胞増殖を処置するための方法および材料 Pending JP2024508749A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163150232P 2021-02-17 2021-02-17
US63/150,232 2021-02-17
PCT/US2022/016423 WO2022177889A1 (en) 2021-02-17 2022-02-15 Methods and materials for treating clonal t cell expansions

Publications (2)

Publication Number Publication Date
JP2024508749A JP2024508749A (ja) 2024-02-28
JP2024508749A5 true JP2024508749A5 (enExample) 2025-02-17

Family

ID=80595091

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023549562A Pending JP2024508749A (ja) 2021-02-17 2022-02-15 クローンt細胞増殖を処置するための方法および材料

Country Status (7)

Country Link
US (1) US20240124608A1 (enExample)
EP (1) EP4294841A1 (enExample)
JP (1) JP2024508749A (enExample)
CN (1) CN117561277A (enExample)
AU (1) AU2022222679A1 (enExample)
CA (1) CA3211203A1 (enExample)
WO (1) WO2022177889A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120076829A (zh) 2022-10-18 2025-05-30 明治制果药业株式会社 T细胞肿瘤的治疗剂
JP2026524330A (ja) * 2023-06-28 2026-07-22 ザ・ジョンズ・ホプキンス・ユニバーシティ Trbc標的化抗体薬物複合体
WO2025220689A1 (ja) * 2024-04-17 2025-10-23 Meiji Seikaファルマ株式会社 T細胞機能不全のt細胞性腫瘍患者に有効な二重特異性抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2744046C2 (ru) * 2014-03-05 2021-03-02 Отолус Лимитед ХИМЕРНЫЙ АНТИГЕННЫЙ РЕЦЕПТОР (CAR) С АНТИГЕНСВЯЗЫВАЮЩИМИ ДОМЕНАМИ К КОНСТАНТНОЙ ОБЛАСТИ β Т-КЛЕТОЧНОГО РЕЦЕПТОРА
GB201709203D0 (en) * 2017-06-09 2017-07-26 Autolus Ltd Antigen-binding domain
GB201817172D0 (en) * 2018-10-22 2018-12-05 Autolus Ltd Antibody
GB201817822D0 (en) * 2018-10-31 2018-12-19 Autolus Ltd Binding domain

Similar Documents

Publication Publication Date Title
JP2023551535A5 (enExample)
Reinherz et al. Loss of suppressor T cells in active multiple sclerosis: analysis with monoclonal antibodies
JP2021530987A5 (enExample)
JP2022061993A5 (enExample)
JP2022512917A5 (enExample)
JP2022513062A5 (enExample)
JP2023526774A5 (enExample)
JP2020537644A5 (enExample)
CN110741018A (zh) 抗原结合结构域
JP2020529830A5 (enExample)
JP2021523122A5 (enExample)
JP2023519099A5 (enExample)
JP7704748B2 (ja) 逐次抗cd19治療
JP2021512107A5 (enExample)
JP2023522857A5 (enExample)
Kamakura et al. Mechanism of action of a T cell-dependent bispecific antibody as a breakthrough immunotherapy against refractory colorectal cancer with an oncogenic mutation
FR2841905A1 (fr) Fragments fab mutants de l'anticorps anti-cd4 chimere 13b8.2 et leurs applications
JP2022544825A5 (enExample)
KR20230086674A (ko) 파킨슨 질환의 치료
JP2024508749A (ja) クローンt細胞増殖を処置するための方法および材料
JP2021524451A5 (enExample)
Morishige et al. Complete response following toxic epidermal necrolysis in relapsed adult T cell leukemia/lymphoma after haploidentical stem cell transplantation: S. Morishige et al.
Dinov et al. Current and emerging therapies for autoimmune encephalitis
HUE026740T2 (en) Treatment of Multiple Sclerosis (MS) with Campath-1H
JP2024513054A5 (enExample)